Clinical utility of an oral fluid NT-proBNP in heart failure
Research type
Research Study
Full title
Investigating diagnostic and screening utility of an oral fluid NT-proBNP in patients with suspected heart failure.
IRAS ID
323647
Contact name
Michael Fisher
Contact email
Sponsor organisation
Royal Liverpool and Broadgreen University Hospital NHS Trust
Duration of Study in the UK
1 years, 11 months, 31 days
Research summary
The study involves testing the clinical utility of an oral fluid heart failure biomarker NT-proBNP.
The following diagnostic parameters of an oral fluid NT-proBNP biomarker will be assessed as part of the study: diagnostic cut-off level, sensitivity, specificity as well as positive and negative predictive values. Such data will validate the use of NT-proBNP biomarker to rule in or rule out heart failure in a clinical setting.Undifferentiated patients who are referred to the outpatient cardiology clinic with suspected heart failure diagnosis are eligible to take part in the study.
The study will be conducted at the Royal Liverpool Hospital, where oral fluid sample will be taken from each study participant. Blood samples will be also taken from the same study participants as part of the routine care to test serum NT-proBNP levels.
The study will last for approximately one year, until we generate enough data to test the diagnostic applicability of an oral fluid NT-proBNP biomarker in patients with suspected heart failure.
REC name
London - Chelsea Research Ethics Committee
REC reference
23/PR/0233
Date of REC Opinion
3 May 2023
REC opinion
Further Information Favourable Opinion